07:00 , Jul 7, 2008 |  BioCentury  |  Finance

Ebb & Flow

Fewer than one-fifth of the 660 or so VCs queried by the...
00:59 , Jul 3, 2008 |  BC Extra  |  Financial News

MiddleBrook falls on financing plans

MiddleBrook (NASDAQ:MBRK) fell $1.55 (50%) to $1.52 on Wednesday after announcing an agreement with Equity Group Investments (EGI) to raise $100 million. EGI will purchase 30.3 million shares at $3.30, which is a 7% premium...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

MiddleBrook infectious news

MiddleBrook (formerly Advancis Pharmaceutical Corp. ) retained Morgan Stanley and Pacific Growth Equities LLC to seek strategic alternatives, including partnering its products or selling part or all of the company. The company originally said it...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Clinical News

Moxatag amoxicillin pulsys regulatory update

FDA approved an NDA from MiddleBrook (formerly Advancis Pharmaceutical Corp. ) for 775 mg Moxotag extended-release amoxicillin tablets to treat patients aged 12 and up with pharyngitis/tonsillitis secondary to Streptococcus pyogenes infection (strep throat). The...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Company News

MiddleBrook, Deerfield Management Company L.P. deal

Healthcare investment fund Deerfield acquired MBRK's Keflex cephalexin business, excluding Keflex Pulsys, for $7.5 million up front. MBRK has an option to reacquire the assets for $11 million. If MBRK's Amoxicillin Pulsys receives FDA approval,...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Advancis infectious news

AVNC changed its name to MiddleBrook Pharmaceuticals Inc. and its ticker to MBRK. Advancis Pharmaceutical Corp. (AVNC), Germantown, Md.   Business: Infectious  ...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

Keflex Pulsys: Phase III start

MBRK (formerly Advancis Pharmaceutical Corp. ) will begin a double-blind, non-inferiority Phase III trial in >=600 patients to compare 1,200 mg Keflex PULSYS once daily vs. 250 mg of Keflex cephalexin 4 times daily for...
07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

Amoxicillin Pulsys regulatory update

FDA accepted for filing an NDA for once-daily Amoxicillin Pulsys to treat adolescents and adults with pharyngitis/tonsillitis. The PDUFA date is Jan. 23, 2008. In March, AVNC resubmitted the NDA under section 505(b)(2) of the...
01:05 , May 23, 2007 |  BC Extra  |  Company News

FDA accepts Amoxicillin Pulsys NDA

Advancis (AVNC) gained $0.37 (14%) to $3.10 on Tuesday after FDA accepted for filing an NDA for once-daily Amoxicillin Pulsys to treat adolescents and adults with pharyngitis/tonsillitis. The PDUFA date is Jan. 23, 2008. AVNC...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Company News

Advancis board of directors update

Advancis Pharmaceutical Corp. (AVNC), Germantown, Md.   Business: Infectious   Appointed: Martin Vogelbaum, a partner at Rho Ventures  ...